Ascentage Pharma Group International
NASDAQ:AAPGBiotechnology
+$0.31 today
- Market cap
- $1.16B
- Beta
- 0.65
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$13.29
Volume 0.00M
Average 0.01M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Ascentage Pharma Group International
NASDAQ:AAPG
Intrinsic Alpha fair value
Locked
Current Price
$12.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +38.6% | +68.6% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +38.6% over three years. Forward estimates point to Revenue at +68.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Tango Therapeutics, Inc. NASDAQ:TNGX | $4.32B | $25.50 | Not rated | -38.9 | +155.17% |
IDEAYA Biosciences, Inc. NASDAQ:IDYA | $3.08B | $31.83 | Not rated | -19.5 | -21.08% |
Zai Lab Limited NASDAQ:ZLAB | $2.78B | $24.60 | Not rated | -11.4 | +8.46% |
Nurix Therapeutics, Inc. NASDAQ:NRIX | $1.69B | $15.48 | Undervalued | -6.4 | -11.29% |
Nuvation Bio Inc. NYSE:NUVB | $1.40B | $3.99 | Not rated | -12.8 | -45.65% |
Verastem, Inc. NASDAQ:VSTM | $1.03B | $8.18 | Not rated | -2.1 | -30.07% |
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP | $672.92M | $13.01 | Not rated | -9.8 | -43.87% |
Adlai Nortye Ltd. NASDAQ:ANL | $563.18M | $10.61 | Not rated | -3.0 | +533.57% |
C4 Therapeutics, Inc. NASDAQ:CCCC | $362.43M | $2.76 | Not rated | -4.9 | +2.52% |
Immuneering Corporation NASDAQ:IMRX | $240.27M | $3.71 | Not rated | -3.6 | -50.64% |
Continue the stock analysis
Jump to another research area for this company.